A generic version of Pfizer's blood pressure drug Norvasc could hit the market soon following a legal setback for the drugmaker. A federal Court of Appeals reversed a lower court ruling that supported Pfizer's patent against a challenge by Canadian generic drugmaker Apotex. Mylan Laboratories also aims to market a generic version.

Related Summaries